PureFacts Financial Solutions acquires Quartal Financial Solutions to become a global WealthTech leader
PureFacts Financial Solutions, a leading WealthTech provider of fees, reporting and AI-powered predictive analytics solutions, has acquired Quartal Financial Solutions, Europe’s leading provider of fee billing and commission solutions for the financial and insurance industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117006164/en/
PureFacts Financial Solutions acquires Quartal Financial Solutions (Graphic: Business Wire)
This acquisition further strengthens PureFacts’ ability to provide mission critical, AI-driven and regulatory compliant fee solutions to its marquee clients. Additionally, the combined organization expands the company’s global reach to bring market-leading solutions and opportunities to all its stakeholders.
These two successful companies both have industry-leading expertise in calculating fees and commissions. Together, they will provide the most powerful fee platform in the global financial marketplace. The combined entity will benefit from strengthening their core capabilities in data aggregation, machine learning and financial industry expertise.
This is the second successful acquisition completed by PureFacts this year, coming on the heels of its acquisition of CRM consulting firm, VennScience in May 2020. Led by Gerard Daniels, PureFacts Head of Corporate Development and supported by world class advisors including PricewaterhouseCoopers Corporate Finance Inc. and Goodmans LLP, the team continues to identify strategic acquisitions that best serve its clients and accelerate PureFacts’ strategy.
PureFacts global head office will remain in Toronto, Canada while the European head office will be located at Quartal’s office in Zurich, Switzerland. PureFacts CEO Robert Madej will take the helm of the new corporate entity, with PureFacts President Rajini McRae expanding her role to include the global businesses. Quartal CEO Thierry Zuppinger has been appointed as the General Manager Europe and Asia for the combined entity.
“With any acquisition or partnership that we undertake, we always ensure our values are aligned and our clients’ interests are at the centre,” says Robert Madej, PureFacts CEO. “In this case, we are further excited by the Quartal team’s enthusiasm and the willingness of the key executive team to become shareholders in PureFacts.”
“We are thrilled about the combination of our businesses and are looking forward to working with Rob and his team, who have proven to be a perfect fit as a strategic partner to Quartal’s business going forward,” says Thierry Zuppinger, CEO of Quartal Financial Solutions. “Joining forces with PureFacts will significantly accelerate our joint journey to becoming a truly global market and mindshare leader in the fee and commission management domain; allowing us to better service our clients globally.”
Quartal Financial Solutions is a market-leading provider of fee and commission management, and revenue and expense lifecycle management software for the financial and insurance industries. The company was founded in 1999 and currently has more than 30 clients with over 50 software installations in 15 countries across Europe, United States, Middle East, Africa, and the Asia-Pacific region. Their clients enjoy reduced operating costs, higher performances, quick Return on Investment, and reduced technology obsolescence through the use of their technologically advanced solutions. www.quartalfs.com
Ranked a WealthTech100 Company and Top 12 Canadian Innovator, PureFacts Financial Solutions provides wealth management solutions for the financial services industry in Canada, the USA, and Europe. PureFacts’ mission is to create meaningful wealth solutions that help people live their best lives. They provide their clients with transformational WealthTech solutions to future-proof their business and accelerate growth by leveraging their expertise in wealth management data aggregation, complex calculations, Artificial Intelligence and machine learning. www.purefacts.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117006164/en/
Contact information
Mr. Gerard Daniels
Head of Corporate Development, PureFacts
gerard.daniels@purefacts.com
Mr. Thierry Zuppinger
CEO, Quartal Financial Solutions
thierry.zuppinger@quartalfs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 14:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance
Janssen Submits Marketing Authorisation Extension to the European Medicines Agency to Register Paliperidone Palmitate 6-Monthly (PP6M) for Treatment of Schizophrenia in Adults4.12.2020 12:01:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Marketing Authorisation Extension Application to the European Medicines Agency (EMA) to register paliperidone palmitate 6-monthly (PP6M) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on paliperidone palmitate 1‑monthly (PP1M)1 or 3-monthly (PP3M)2 injectable products. If approved, this long‑acting injectable will provide adults living with schizophrenia a twice-yearly dosing regimen, the longest dosing interval available for an antipsychotic medication in the European Economic Area.3 “Janssen’s roots in neuroscience began with research and development of novel therapeutic options for schizophrenia, and this filing builds on that 60-year commitment,” said Bill Martin, Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC. “We designed this unique dosing regimen so people with schizophrenia and their healthcare team can focus less on medication inte
Patrice Bula to be appointed as new Chairman of Froneri4.12.2020 11:30:00 EET | Press release
After more than 4 years as Chairman of Froneri, Luis Cantarell has expressed his desire to step down at the end of December 2020. Luis’s strategic vision, in-depth knowledge of the Ice Cream business as well as his energizing and inspirational leadership were decisive factors in the forming and ensuing success of Froneri, a joint-venture partnership between Nestlé and PAI Partners created in September 2016. Under Luis’s leadership, Froneri has achieved rapid sales and profit growth, steadily gaining market shares. With presence in 23 markets, a portfolio of iconic brands and an exceptional management team, Froneri is now well-placed to achieve global leadership in the Ice Cream category. To replace Luis, we are pleased to announce the nomination of Patrice Bula, currently Executive Vice President at Nestlé and a Supervisory Board Member of Froneri, and this since its creation. With a rich career spanning more than 40 years with Nestlé SA, of which the last 10 as Executive Vice Presiden
Xlife Sciences AG: Successful Capital Raising of Six Million Swiss Francs4.12.2020 11:00:00 EET | Press release
Capital increase of Xlife Sciences AG Successful capital raising of six million Swiss francs Xlife Sciences AG has successfully closed its capital increase and raised a total of 6.02 million Swiss Francs of new capital as of December 3, 2020. The placement was oversubscribed at the end of the subscription period. The management of the company sees the strong demand as a confirmation for its business model. The capital will be used almost exclusively for existing and new projects. In the capital round completed on December 3, 2020, existing and new investors subscribed for shares with a total value of CHF 6.02 million. For Oliver R. Baumann, CEO of Xlife Sciences AG, the high demand of investors is a confirmation of the successful business model. "The strong interest of investors shows that our company, with its strategy of holding and developing a broad portfolio of early-stage life science projects is an attractive investment even in challenging times such as the corona crisis". Inves
Rand Technology Appoints Key Executives Across Global Regions4.12.2020 02:30:00 EET | Press release
Rand Technology (Rand) has appointed Kim Fix, Chief Operating Officer (COO), Americas & Europe; Frederick Fu, President and Managing Director, Asia-Pacific (APAC); Nami Mokri, Vice President, Sales & Sourcing, APAC; Kevin Sheehan, Chief Information Officer (CIO); and Jennifer Strawn, Director, Sourcing & Procurement, Americas & Europe. Kim Fix, Global Vice President, QA & Operations, has been appointed to COO, Americas & Europe. Kim will lead Rand’s sales and sourcing teams’ operations across the Americas and Europe and oversee global compliance, quality assurance, and operations. Kim has been integral to Rand’s preferred status with its business partners and multi-site ISO, OHSAS, ANSI ESD, and R2 certifications. Frederick Fu joined Rand as President and Managing Director, APAC. He previously served as Avnet’s President of APAC. He has been fundamental to Rand’s efficacy, growth, strategy, and success in the APAC region. Nami Mokri was appointed Vice President, Sales & Sourcing, APAC.
Kalray Joins MLCommons as Founding Member3.12.2020 20:30:00 EET | Press release
Kalray (Euronext Growth Paris: FR0010722819 – ALKAL) (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined MLCommons as founding member. MLCommons is a not for profit, engineering consortium founded by 30+ global technology and academic leaders in AI and Machine Learning to accelerate machine learning innovation and broaden access to this critical technology for the public good. Initially formed as MLPerf, MLCommons boasts a founding board that includes representatives from Alibaba, Facebook AI, Google, Intel, NVIDIA and Professor Vijay Janapa Reddi of Harvard University with the objective to deliver industry-wide benchmarks, best practices and datasets to speed computer vision, natural language processing, and speech recognition development for all. “MLCommons has a clear mission - accelerate Machine Learning innovation to ‘raise all boats’ and increase its positive impact on society” said Peter Mattson, President of MLCommons. “We are excit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom